February 7, 2024 News by Marisa Wexler, MS New MRI technique allows for more precise imaging of myelin sheath Scientists have developed a technique to more precisely map the myelin sheath, the fatty covering around nerve fibers that is damaged in multiple sclerosis (MS), in people undergoing an imaging scan. While further work is needed, its use “produced promising initial results,” the scientists wrote, noting that this…
November 3, 2023 News by Marisa Wexler, MS AI tool has potential to better track MS lesions over time: Study An artificial intelligence (AI) program, called iQ-MS, outperforms traditional radiologist-based measures at quantifying changes in lesions over time in people with multiple sclerosis (MS), a new study shows. “iQ-MS is a sensitive and accurate tool for monitoring MRI scans in people with MS by providing quantitative metrics that value-add…
October 11, 2023 Columns by Mike Parker Dragged into my MS diagnosis, but now jumping for a cure: Part 1 Multiple Sclerosis News Today is chronicling MS advocate and podcaster Mike Parker’s journey leading up to a skydiving jump he’ll be making on Oct. 29 to benefit the MS Society U.K. Learn more about Mike at his website mikesmsjourney.com and click here to donate to his fundraiser.
September 15, 2023 News by Andrea Lobo, PhD Benefits of long-term Tysabri seen in RRMS patients in Japan: Study Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple sclerosis (RRMS), according to a new study. The therapy also eased or stabilized disability levels in most patients after five years of treatment, and significantly reduced the annual rate of…
September 5, 2023 News by Margarida Maia, PhD MS Australia awards incubator grants to four research projects Four researchers working in multiple sclerosis (MS) were awarded incubator grants in MS Australiaās latest funding round, which theyāll use to kickstart projects designed to better understand the progressive neurodegenerative disease. Worth a total of AU$92,565, or roughly $60,000, this round of incubator grants provides seed funding…
July 3, 2023 News by Patricia Inacio, PhD Potentially safer MRI gadolinium-based contrast agent to enter testing Gadoquatrane, a gadolinium-based contrast agent (GBCA) that may be safer than current agents for people undergoing MRI scans, has entered a Phase 3 clinical testing program. Quanti CNS (NCT05915702), one of the three global trials in Bayer‘s development program, will assess gadoquatrane against an…
March 21, 2023 News by Margarida Maia, PhD Early MS MRI markers linked to worse disability in 10 years time MRI scans of the brain acquired early on after the onset of multiple sclerosis (MS) may help predict disease severity and disability accumulation after 10 years, a new study found. In particular, there were two MRI biomarkers ā inter-caudate diameter (ICD) and third ventricular width (TVW) ā detected…
March 9, 2023 News by Lindsey Shapiro, PhD Icobrain MS, an AI tool for assessing MRI scans, being tested in UK An upcoming study will investigate how well icobrain MS, anĀ artificial intelligence (AI)-based technology,Ā can interpret MRI dataĀ from people with multiple sclerosis (MS) and how its use might influence patient care. The project, called AssistMS and led by IcometrixĀ ā the technology’s developer ā and Queen Mary University of London…
November 29, 2022 News by Mary Chapman Pixyl, Brainomix Partner on MRI Software to Help in Diagnosis of MS In a new collaboration, Brainomix will distribute in Europe a software solution developed by Pixyl that uses deep learning to improve the diagnosis and monitoring of multiple sclerosis (MS) via MRI scans. According to the partners, Pixyl‘s technology can detect abnormalities on magnetic resonance imaging or MRI…
July 18, 2022 News by Marisa Wexler, MS Certain MS Lesions Linked to Worse Disability, but Location Not a Factor The presence ofĀ iron rim lesions (IRLs), which are regions of chronic nervous system damage with ongoing inflammation, visible on MRI scans, is linked with more substantial disability in people with multiple sclerosis (MS),Ā according to a new study. However, the connection between these lesions and worse disability does not…
July 6, 2022 News by Marisa Wexler, MS Researchers Distinguish Remyelinated Brain Lesions Via MRI An MRI technique called quantitative susceptibility mapping (QSM) can be used to accurately identify remyelinated brain lesions in people with multiple sclerosis (MS), a research team has discovered. Remyelinated lesions are those in which the myelin sheath ā the protective coating around nerve fibers that is progressively lost…
October 14, 2021 News by Marisa Wexler, MS #ECTRIMS2021 ā Brain Lesions Help Predict Long-term Disability Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ here to see the latest stories from the…
July 9, 2021 News by Steve Bryson, PhD Cambridge-1 ‘Supercomputer’ to Advance UK Research in Ills Like MS Nvidia announced the launch of the U.K.ās most powerful supercomputer ā calledĀ Cambridge-1 ā which uses a combination of artificial intelligence (AI) and simulation to help scientists to better understand complex diseases such as multiple sclerosis (MS) and to design new therapeutics. Cambridge-1 is the first supercomputer designed…
December 12, 2019 Columns by Tamara Sellman Need to Know: MS and Smoldering Lesions Editor’s note: “Need to Knowā is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by two forum topics about silent inflammation from August 2019. Have an experience you want…
December 14, 2016 News by Joana Fernandes, PhD Gadolinium, an MRI Contrast Agent That Accumulates in Brain, May Contribute to MS Certain contrast agents used during magnetic resonance imaging (MRI) may accumulate in specific brain areas and contribute to disease duration and severity in patients with multiple sclerosis (MS), according to a new study published in the Multiple Sclerosis Journal. The study, “Gadopentetate But Not Gadobutrol Accumulates In The…
August 15, 2016 News by Patricia Silva, PhD Treating MS Soon After Symptoms Appear Can Delay Relapses, Study Says A long-term study underscoresĀ the potentialĀ benefits, especially in terms of relapses,Ā ofĀ multiple sclerosis (MS) patients beginning treatment as soon as possible after symptomsĀ appear ā even before the disease is definitely diagnosed.Ā āThe 11-year long-term follow-up study from the randomized BENEFIT CIS trialā was published in the journal Neurology. Researchers in…
February 17, 2016 News by Patricia Inacio, PhD For MS Patients, New Guidelines for Controlling Rare Brain Infection Risk Under Tysabri Treatment The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC), responsible for assessing and monitoring safety issues for human medicines, completedĀ a review on the risk for progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with the medicine Tysabri (natalizumab). The issued guidelines have the objective of minimizing patientsā risk.
January 29, 2016 News by Patricia Silva, PhD Guidelines Issued for Monitoring of MS Patients on Natalizumab Treatment A panel of neurologists from the U.K. and Ireland recently developed practical consensus guidelines for monitoring multiple sclerosis (MS) patients on natalizumab (Tysabri)Ā therapy for the risk of developing progressive multifocal leukoencephalopathy (PML), a life-threatening viral infection caused by the John Cunningham (JC) virus. The panel was summoned by…